Results 111 to 120 of about 67,645 (203)

The interplay of multimorbidity and depressive symptoms: mediation role of functional dependence

Epidemiology and Psychiatric Sciences
Objective Mental–physical multimorbidity is an emerging prevalent global health challenge. This study aims to examine reciprocal relationships between depressive symptoms and multimorbidity, with the mediation role of functional dependence in activities ...
Rui She, Haiyue Luo, Shanquan Chen, Fangfei Xiong, Karen P. Y. Liu, Marco Y. C. Pang   +5 more
doaj   +1 more source

Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe

The Lancet Public Health, 2017
Summary: Background: Although overweight and obesity have been studied in relation to individual cardiometabolic diseases, their association with risk of cardiometabolic multimorbidity is poorly understood.
Mika Kivimäki, ProfPhD, Eeva Kuosma, MSc, Jane E Ferrie, PhD, Ritva Luukkonen, PhD, Solja T Nyberg, MSc, Lars Alfredsson, ProfPhD, G David Batty, PhD, Eric J Brunner, PhD, Eleonor Fransson, PhD, Marcel Goldberg, ProfMD, Anders Knutsson, ProfPhD, Markku Koskenvuo, MD, Maria Nordin, PhD, Tuula Oksanen, PhD, Jaana Pentti, MSc, Reiner Rugulies, ProfPhD, Martin J Shipley, MSc, Archana Singh-Manoux, PhD, Andrew Steptoe, ProfPhD, Sakari B Suominen, MD, Töres Theorell, ProfMD, Jussi Vahtera, ProfMD, Marianna Virtanen, ProfPhD, Peter Westerholm, ProfMD, Hugo Westerlund, ProfPhD, Marie Zins, MD, Mark Hamer, ProfPhD, Joshua A Bell, PhD, Adam G Tabak, PhD, Markus Jokela, PhD   +29 more
doaj   +1 more source

Impact of obstructive sleep apnea on prognosis of patients with cardiometabolic multimorbidity

Diabetology & Metabolic Syndrome
Abstract Background Cardiometabolic multimorbidity (CMM) is a growing global health problem, and obstructive sleep apnea (OSA) is recognized as an important risk factor for cardiovascular disease. However, the impact of OSA on the prognosis of CMM patients remains unclear. Methods
Xiaogang Liu, Siyi Li, Xiao Wang, Jingyao Fan, Wei Gong, Yan Yan, Hui Ai, Bin Que, Wen Zheng, Shaoping Nie   +9 more
openaire   +3 more sources

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, Volume 34, Issue 11, Page 2051-2060, November 2026.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Accelerated biological aging elevates the risk of cardiometabolic multimorbidity and mortality

Nature Cardiovascular Research
Associations of biological aging with the development and mortality of cardiometabolic multimorbidity (CMM) remain unclear. Here we conducted a multistate analysis in 341,159 adults of the UK Biobank. CMM was defined as the coexistence of two or three cardiometabolic diseases (CMDs), including type 2 diabetes, ischemic heart disease and stroke ...
Meijie Jiang, Sifan Tian, Shuzhen Liu, Yuting Wang, Xinbiao Guo, Tao Huang, Xihong Lin, Daniel W. Belsky, Andrea A. Baccarelli, Xu Gao   +9 more
openaire   +3 more sources

Cardiometabolic multimorbidity and symptoms of common mental disorders in a primary healthcare system for low-income urban population in Pakistan.

PLOS Global Public Health
The objective of the study was to evaluate the prevalence of cardiometabolic multimorbidity and symptoms of common mental disorders, including depression, anxiety, and stress, and association between the two, in primary care clinics for low-income, urban
Rafay Iqbal, Asra Qureshi, Rabia Jaffar, Wajiha Omair, Asif Ali Imam, Unab Inayat Khan   +5 more
doaj   +1 more source

Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6‐Month Claims Database Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9966-9979, November 2026.
ABSTRACT Aims Tirzepatide is a once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) approved in the US for the treatment of Type 2 diabetes (T2D), weight loss and obstructive sleep apnoea. This study aimed to assess the utilisation and effectiveness of tirzepatide among individuals in a large ...
Theresa Hunter Gibble, Malvika Venkataraman, Donna Mojdami, Carlos Vallarino, Grace Stockbower, Michael Grabner, Mythili Ananth, Karishma Desai   +7 more
wiley   +1 more source

Experimental Physiology Special Issue: New approaches for old diseases

Experimental Physiology, EarlyView.
Daniel H. Craighead, Ronan M. G. Berg, Kristen L. Nowak   +2 more
wiley   +1 more source

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10418-10427, November 2026.
ABSTRACT Aims Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025.
Navneet Upadhyay, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R. Hankosky   +5 more
wiley   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10765-10779, November 2026.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source